What is it about?
ABC294640 could downregulate the expression of c-Myc in EOC both in vitro and in vivo. ABC294640 inhibited tumor growth in EOC via cell cycle arrest and inducing cell apoptosis both in vitro and in vivo, partially by decreasing the expression of cell cycle–associated proteins (such as P-Rb, cyclin B1, and cyclin D1) and promoting caspase 3 activation via downregulation expression of c-Myc.
Featured Image
Photo by Element5 Digital on Unsplash
Why is it important?
It suggested that ABC294640 had the potential to serve as an agent in EOC treatment.
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations.
Keqi Song
Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Read the Original
This page is a summary of: Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo, OncoTargets and Therapy, June 2019, Dove Medical Press,
DOI: 10.2147/ott.s208519.
You can read the full text:
Contributors
The following have contributed to this page
